Drug Type Small molecule drug |
Synonyms |
Target |
Action antagonists |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small cell lung cancer limited stage | Phase 3 | China | 16 Apr 2025 | |
Meningioma | Phase 2 | China | 11 Dec 2024 | |
Liver Cancer | Phase 2 | China | 14 Nov 2024 | |
Liver Cancer | Phase 2 | China | 14 Nov 2024 | |
Solid tumor | Phase 2 | - | - | |
Colorectal Cancer | Phase 1 | China | 26 May 2021 | |
High grade glioma | Phase 1 | China | 26 May 2021 | |
Kidney Neoplasms | Phase 1 | China | 26 May 2021 | |
Stomach Cancer | Phase 1 | China | 26 May 2021 | |
Thyroid Cancer | Phase 1 | China | 26 May 2021 |
Phase 1 | 38 | pfniybrcfb(dcaobdvhvc) = TRAEs ≥ grade 3 occurred in more than 2 patients were hypertension (28.9%) and decreased platelet count (10.5%) xcolrussjr (favflairej ) View more | Positive | 15 Sep 2024 | |||
SYHA1813 15mg | |||||||
Phase 1 | 11 | SYHA1813 15mg or 20mg | (khrctueutk) = aplokubsri hyxkjghgdr (mdkqzrepzy, 16.8 - 76.6) View more | Positive | 21 Oct 2023 | ||
Phase 1 | 14 | (btktaxnoqe) = oighevwder iocwybexzk (ifvngtehfh ) View more | - | 08 Mar 2023 | |||
Phase 1 | 14 | (hygohvfxng) = The dose-limiting toxicities (DLTs) were grade (G) 4 hypertension (n = 1) and G3 mucositis oral (n =1) at 30 mg. hgvcsaejom (otuczvoddy ) View more | Positive | 10 Sep 2022 |